Funding for Cancer Research and Control Programs in the President’s FY 2011 Budget

Posted by Catherine Knowles on February 1st, 2010

The fiscal year 2011 budget process got underway today when President Obama sent Congress his budget proposal.  The President’s $3.8 trillion budget includes a three-year freeze on non-security discretionary spending in order to save about $250 billion over 10 years and start narrowing the $1.6 trillion gap between proposed budget outlays and tax receipts.  The freeze caps the overall level of spending so that some programs get increases (for example, cancer research at NIH and NCI receives a funding increase), while other programs (including some of the cancer control programs at the CDC) are cut.  The freeze comes on top of a proposal to eliminate, or scale back, 120 programs in order to save more than $20 billion.

U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius issued the following statement of support,

“[u]nder this budget, we will provide the health and human services that Americans depend on more effectively, slashing waste and focusing programs on results.  And we’ll make many of the necessary investments our country has been putting off for years, including investments in fighting health care fraud, strengthening our public health infrastructure, and getting serious about health and wellness,” said Sebelius. “This budget is a big step toward a healthier, stronger America.” Read the rest of this entry »

Tags: , , , , Comments (0): Add a comment

FDA approves highly concentrated liquid morphine for severe pain

Posted by Kate Murphy on January 29th, 2010

In good news for cancer patients at the end of life,  the Food and Drug Administration has approved a concentrated liquid morphine to relieve acute and chronic pain in patients where other opiates are no longer working.

Although concentrated doses of liquid morphine have used to manage pain for opiate-tolerant patients for some time, the oral concentrated dose was not FDA approved.

The FDA has worked with Roxane Laboratories, the only manufacturer of the 20mg/mL formulation, to be sure that adequate supplies are available to patients in need.  Read the rest of this entry »

Tags: , Comments (0): Add a comment

Colorectal Cancer News Briefs: January 20

Posted by Kate Murphy on January 20th, 2010

This week we’re sending you news about SMARxT Disposal of leftover medicine and a new resource from FDA that makes finding information on their website easier.

We’re experimenting with a little different format for the weekly briefs. You’ll find two different blogs — one with research news and another with upcoming events and consumer information. In this way, we hope to include a bit more detail while still keeping the individuals items brief and easy to read.

Watch for Kate Murphy on Twitter this weekend.  She’ll be sending Tweets from the ASCO GI Symposium in Orlando.  Follow C3 news and research updates @FIGHTCRC.   Here’s more information on joining Twitter to follow C3. Read the rest of this entry »

Tags: , Comments (2): Add a comment

Colorectal Cancer News in Brief: December 29

Posted by Kate Murphy on December 29th, 2009

Briefly

Factors related to the patient, year of surgery, and tumor itself and not surgeons or pathologists explain low lymph node counts after colon and rectal surgery.  Lack of colorectal cancer screening leads to emergency surgery and complications and death among the elderly.

Americans without health insurance are more likely to die, even when factors like overall health, smoking, and income are considered, and cancer patients who have support from family and friends at diagnosis are much more likely to look on the entire experience as a chance for positive growth years later.

Finally, FDA has a good video to help people avoid health care frauds.

Happy Holidays.  Enjoy family, friends, and lights. Read the rest of this entry »

FDA Authorizes Emergency Use of IV Peramivir for Some H1N1 Patients

Posted by Kate Murphy on October 25th, 2009

In response to a request from the Centers for Disease Control, the Food and Drug Administration will allow emergency use of the investigational antiviral intravenous drug peramivir in some hospitalized patients with 2009 H1N1 influenza infection.  The Emergency Use Authorization (EUA) is effective for both adults and children from birth to age 17.

There are currently no intravenous (IV) antiviral medicines approved for influenza.  Read the rest of this entry »

Tags: , , Comments (0): Add a comment
Page 7 of 17« First...56789...Last »